KAZUHITO NAKA

Last Updated :2023/06/07

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, Associate Professor
Web Site
https://archive.hiroshima-u.ac.jp/koho_press/HiroshimaUniversityUpdate_202102_1.pdf
https://www.nature.com/articles/s41467-020-18491-9
http://www.nature.com/ncomms/2015/150820/ncomms9039/full/ncomms9039.html
https://www.nature.com/articles/nature08734
E-mail
kanaka55hiroshima-u.ac.jp
Self-introduction
Chronic myelogenous leukemia (CML) stem cells, which are the cell-origin of the vast majority of mature CML cells, are responsible for the development and relapse of CML disease. The purpose of my research is to develop novel therapeutics for eradicating CML stem cells in vivo.

Basic Information

Major Professional Backgrounds

  • 1993/04/01, 1995/06/30, Daicel Corporation, Department of Production, Researcher
  • 2000/04/01, 2003/01/31, National Center for Geriatrics and Gerontrogy, Department of Geriatrics, Post doctoral fellow
  • 2003/02/01, 2005/06/30, Okayama University Graduate School of Medicine and Dentistry, Department of Molecular Biology, Post doctoral fellow, and Assistant Professor
  • 2005/07/01, 2011/02/09, Kanazawa University, Cancer Research Institute, Division of Molecular Genetics, Assistant Professor, and Associate Professor
  • 2011/02/10, 2015/03/31, Kanazawa University, Cancer Research Institute, Exploratory Project on Cancer Stem Cells, Associate Professor
  • 2015/04/01, Hiroshima University, Research Institute for Radiation Biology and Medicine, Department of Stem Cell Biology, Associate Professor

Educational Backgrounds

  • Hiroshima University, Graduate School of Medicine.
  • Okayama University Graduate School of Engineering

Academic Degrees

  • Hiroshima University
  • Okayama University

Research Fields

  • Biological Sciences;Oncology;Tumor biology
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Hematology
  • Medicine,dentistry, and pharmacy;Basic medicine;General medical chemistry
  • Medicine,dentistry, and pharmacy;Basic medicine;Pathological medical chemistry
  • Medicine,dentistry, and pharmacy;Basic medicine;Experimental pathology

Research Keywords

  • Cancer Stem Cells
  • Hematopoietic stem cells
  • Stem Cell Biology
  • Chronic Myelogenous Leukemia (CML) Stem Cells
  • Mouse model for breast cancer stem cells
  • TGF-beta/FOXO
  • Lipidomics
  • Lysophospholipid Metabolism
  • Deep Learning
  • Bio digital transformation (Bio-DX)

Affiliated Academic Societies

Educational Activity

Course in Charge

  1. 2023, Graduate Education (Master's Program) , First Semester, Molecular Biology and Radiological Science
  2. 2023, Graduate Education (Doctoral Program) , Second Semester, Introduction to Radiation Biology

Research Activities

Academic Papers

  1. ★, The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells, Nature Communications, 11, 4681, 20200917
    Link to Paper Search Results by DOI
  2. ★, Dipeptide species regulate p38-MAPK-Smad3 signalling to maintain chromic myelogenous leukaemia stem cells., Nature Communications, 6:8039 doi: 10.1038/ncomms9039., 20150820
    Link to Paper Search Results by DOI
  3. ★, TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia, Nature, 463(7281), 676-680, 2010
    Link to Paper Search Results by DOI
  4. ★, Foxo3a is essential for maintenance of the hematopoietic stem cell pool, Cell Stem Cell, 1(1), 101-112, 2007
    Link to Paper Search Results by DOI
  5. ★, Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription., EMBO J. , 21(19), 5195-5205, 2002
    Link to Paper Search Results by DOI
  6. Generation of Philadelphia chromosome in human leukemia by DNA breaks on the BCR and ABL1 genes using CRISPR/Cas9 system., Cancer Gene Therapy,, 20230101
    Link to Paper Search Results by DOI
  7. Pterostilbene administration downregulates BCR/ABL and induces apoptosis in T315I-mutated BCR/ABL-positive leukemic cells., Sci. Rep., 12, 704, 20220113
    Link to Paper Search Results by DOI
  8. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia., Cancer Sci., 113(2), 529-539, 20211213
    Link to Paper Search Results by DOI
  9. Statins synergistically potentiate the eradication of leukemic stem cells and enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors, Cancers, 13(21), 5543, 20211104
    Link to Paper Search Results by DOI
  10. Role of lysophospholipid metabolism in chronic myelogenous leukemia stem cells (Review), Cancers, 13(14), 3434, 20210708
    Link to Paper Search Results by DOI
  11. New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism (Review)., International Journal Hematology, 11(5), 648-655, 20210305
    Link to Paper Search Results by DOI
  12. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer, Cancer Sci., 112(3), 1196-1208, 20210110
    Link to Paper Search Results by DOI
  13. Targeting of plasminogen activator inhibitor-1 promotes elimination of chronic myeloid leukemia stem cells., Haematologica, 106(2), 483-494, 202102
    Link to Paper Search Results by DOI
  14. Uc.63+ contributes to gastric cancer progression through regulation of NF-kappaB signaling., Gastric Cancer, 20200422
    Link to Paper Search Results by DOI
  15. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell, ONCOGENE, 39(50), 7265-7278, 20201210
    Link to Paper Search Results by DOI
  16. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia doi: 10.1038/s41375-018-0321-8, Leukemia, 33(6), 1439-1450, 20181216
    Link to Paper Search Results by DOI
  17. Genetic regulation of the RUNX transcription factor family has antitumor effects., J Clin Invest., 127(7), 2815-2828, 20170522
    Link to Paper Search Results by DOI
  18. Novel oral transforming growth factor-beta signaling inhibitor EW-7197 eradicates CML-initiating cells., Cancer Sci., 107(2), 140-148 doi: 10.1111/cas.12849, 2016
    Link to Paper Search Results by DOI
  19. Manipulation of cell cycle and chromatin configuration by means of cell-penetrating Geminin., PLOS ONE, 11(5), e0155558, 201605
    Link to Paper Search Results by DOI
  20. New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment (Perspective), Stem Cell Investigation, 3, doi:10.21037/sci.2016.05.05, 20160603
    Link to Paper Search Results by DOI
  21. A novel splenic B1 regulatory cell subset suppresses an allergic disease via PI3K-Akt pathway activation., J Allergy Clin Immunol., doi: 10.1016/j.jaci.2015.12.1319, 2016
    Link to Paper Search Results by DOI
  22. Transcriptome sequencing of hematopoietic stem cells and chronic myelogenous leukemia stem cells., Genomics Data, 7(8), 57-59, doi: 10.1016/j.gdata.2015.11.017, 201603
    Link to Paper Search Results by DOI
  23. Homozygous Deletions at 3p22, 5p14, 6q15, and 9p21 Result in Aberrant Expression of Tumor Suppressor Genes in Gastric Cancer., Genes, Chromosomes and Cancer., 54(3), 142-155, 2015
    Link to Paper Search Results by DOI
  24. Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients, BBRC, 450(1), 837-843, 2014
    Link to Paper Search Results by DOI
  25. Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells, Cancer Sci, 105(4), 418-424, 2014
    Link to Paper Search Results by DOI
  26. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells, PNAS, 111(10), 3805-3810, 2014
    Link to Paper Search Results by DOI
  27. Crosstalk between the Rb Pathway and AKT Signaling Forms a Quiescence-Senescence Switch, Cell Reports, 7(1), 194-207, 2014
    Link to Paper Search Results by DOI
  28. Definition of Smad3 Phosphorylation Events That Affect Malignant and Metastatic Behaviors in Breast Cancer Cells, Cancer Res, 74(21), 6139-6149, 2014
    Link to Paper Search Results by DOI
  29. Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence, Cancer Cell, 23(3), 347-361, 2013
    Link to Paper Search Results by DOI
  30. B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 131(6), 1674-+, 2013
    Link to Paper Search Results by DOI
  31. MIP-1 alpha/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia, JEM, 210(12), 2661-2673, 2013
    Link to Paper Search Results by DOI
  32. Abundant Nucleostemin Expression Supports the Undifferentiated Properties of Germ Cell Tumors, AMERICAN JOURNAL OF PATHOLOGY, 183(2), 592-603, 2013
    Link to Paper Search Results by DOI
  33. mTORC1 is essential for leukemia propagation but not stem cell self-renewal, JOURNAL OF CLINICAL INVESTIGATION, 122(6), 2114-2129, 2012
    Link to Paper Search Results by DOI
  34. Nucleostemin in Injury-Induced Liver Regeneration, STEM CELLS AND DEVELOPMENT, 21(16), 3044-3054, 2012
    Link to Paper Search Results by DOI
  35. NKX2.2 Suppresses Self-Renewal of Glioma-Initiating Cells, Cancer Res, 71(3), 1135-1145, 2011
    Link to Paper Search Results by DOI
  36. Maintenance of genomic integrity in hematopoietic stem cells, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(4), 434-439, 2011
    Link to Paper Search Results by DOI
  37. Molecular pathology of tumor-initiating cells: Lessons from Philadelphia chromosome-positive leukemia, PATHOLOGY INTERNATIONAL, 61(9), 501-508, 2011
    Link to Paper Search Results by DOI
  38. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells, CANCER SCIENCE, 101(7), 1577-1581, 2010
    Link to Paper Search Results by DOI
  39. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin, PNAS, 106(40), 17163-17168, 2009
    Link to Paper Search Results by DOI
  40. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells, ANTIOXIDANTS & REDOX SIGNALING, 10(11), 1883-1894, 2008
    Link to Paper Search Results by DOI
  41. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells, EMBO J, 27(12), 1671-1681, 2008
    Link to Paper Search Results by DOI
  42. Identification of Stem Cells During Prepubertal Spermatogenesis via Monitoring of Nucleostemin Promoter Activity, STEM CELLS, 26(12), 3237-3246, 2008
    Link to Paper Search Results by DOI
  43. Molecular bases for self-renewal and differentiation of leukemic stem cells (Review)., Curr. Cancer Therapy Rev. , 4(3), 178-187, 2008
    Link to Paper Search Results by DOI
  44. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes, MICROBIOLOGY AND IMMUNOLOGY, 51(1), 117-125, 2007
    Link to Paper Search Results by DOI
  45. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA, VIRUS RESEARCH, 125(1), 88-97, 2007
    Link to Paper Search Results by DOI
  46. Regulation of reactive oxygen species by Atm is essential for proper response to DNA double-strand breaks in lymphocytes, JOURNAL OF IMMUNOLOGY, 178(1), 103-110, 2007
    Link to Paper Search Results by DOI
  47. Regulation of the self-renewal ability of tissue stem cells by tumor-related genes (Review)., Cancer Biomarkers , 3(4,5), 193-201, 2007
  48. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells, Nature Medicine, 16(1), 129-129, 2006
    Link to Paper Search Results by DOI
  49. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma., Cancer research, 64(2), 2004
    Link to Paper Search Results by DOI
  50. TNF-alpha/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells., Oncogene, 33(29), 3820-3829, 2013
    Link to Paper Search Results by DOI
  51. Different anti-HCV profiles of strains and their potential for combination therapy with interferon., Hepatology , 44(1), 117-125, 2006
    Link to Paper Search Results by DOI
  52. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells., J. Hepatology. , 44(5), 869-878, 2006
    Link to Paper Search Results by DOI
  53. Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes., Virology , 346(2), 348-362, 2006
    Link to Paper Search Results by DOI
  54. Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptors., J. Gen. Virol. , 86(10), 2787-2792, 2005
    Link to Paper Search Results by DOI
  55. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha., Biochem. Biophys. Res. Commun. , 330(3), 871-879, 2005
    Link to Paper Search Results by DOI
  56. Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells., Biochem. Biophys. Res. Commun. , 336(2), 458-468, 2005
    Link to Paper Search Results by DOI
  57. cDNA microarray analysis of lactoferrin expression in non-neoplastic human hepatocyte PH5CH8 cells., Biochim. Biophys. Acta. , 1721(1-3), 73-80, 2005
    Link to Paper Search Results by DOI
  58. Efficient replication of a full-length hepatitis C virus genome, strain O in cell culture, and development of a luciferase reporter system. , Biochem. Biophys. Res. Commun. , 329(4), 1350-1359, 2005
    Link to Paper Search Results by DOI
  59. Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture. , J. Gen. Virol., 86(3), 645-656, 2005
    Link to Paper Search Results by DOI
  60. cDNA microarray analysis to compare HCVsubgenomic replicon cells with their cured cells, Virus Res. , 107(1), 73-81, 2005
    Link to Paper Search Results by DOI
  61. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondorial mediated apoptosis in gastric cancer cell line TMK-1 cell., Cancer Immunol. Immunother., 54(8), 729-740, 2005
    Link to Paper Search Results by DOI
  62. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype., Biochem. Biophys. Res. Commun. , 323(1), 299-309, 2004
    Link to Paper Search Results by DOI
  63. Stress-induced premature senescence in hTERT-expressing Ataxia Telangiectasia fibroblasts., J. Biol. Chem. , 279(3), 2030-2037, 2004
    Link to Paper Search Results by DOI
  64. DNA damage tumor suppressor gene and genomic instability (Review). , Curr. Opin. Genet. Dev. , 14(1), 11-16, 2004
    Link to Paper Search Results by DOI
  65. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro., Biochem. Biophys. Res. Commun. , 306(3), 756-766, 2003
    Link to Paper Search Results by DOI
  66. Recruitment of NBS1 into PML oncogenic domains (PODs) via interaction with SP100 protein., Biochem. Biophys. Res. Commun., 299(5), 863-871, 2002
    Link to Paper Search Results by DOI
  67. DNA damage-induced G2/M checkpoint activation by histone H2AX and 53BP1., Nat. Cell Biol., 4(12), 993-997, 200212
    Link to Paper Search Results by DOI
  68. Overexpression of retinoic acid receptor beta Induces growth arrest and apoptosis in oral cancer cell lines., Jpn. J. Cancer Res., 92(1), 42-50, 2001
    Link to Paper Search Results by DOI
  69. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines., Int. J. Cancer , 88(6), 992-997, 2000
    Link to Paper Search Results by DOI
  70. Effect of 9-cis-retinoic acid on oral squamous cell carcinoma cell lines., Cancer Lett. , 151(2), 199-208, 2000
    Link to Paper Search Results by DOI
  71. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach (Review)., J. Gastroenterology, 35((Supple12)), 111-115, 2000
  72. Effect of antisense human telomerase RNA (hTR) transfection on the growth of human gastric cancer cell lines., Biochem. Biophys. Res. Commun., 255(3), 753-758, 1999
    Link to Paper Search Results by DOI
  73. Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma., Oncol. Rep. , 6(5), 983-987, 1999
    Link to Paper Search Results by DOI
  74. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesion of the stomach. , Jpn J. Cancer Res., 90(6), 589-595, 1999
    Link to Paper Search Results by DOI
  75. Transfection of Interluekin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice., Br. J. Cancer, 81(4), 647-653, 1999
    Link to Paper Search Results by DOI
  76. Expression of E2F in gastroentestinal carcinomas., Int. J. Cancer, 81(4), 535-538, 1999
    Link to Paper Search Results by DOI
  77. Expression of cell-cycle-regulating transcription factor E2F-1 in colorectal carcinomas. , Pathobiology , 67(4), 174-179, 1999
    Link to Paper Search Results by DOI
  78. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas, Relation to the proliferation and progression. , Int. J. Oncol. , 12(6), 1253-1258, 1998
    Link to Paper Search Results by DOI
  79. Growth inhibition of cultured human gastric cancer cells by 9-cis-retinoic acid with induction of cdk inhibitor Waf1/Cip1/Sdi1/p21 protein. , Differentiation , 61(5), 313-320, 1997
    Link to Paper Search Results by DOI
  80. Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line., Cell Growth Differ., 8(1), 47-52, 1997
    Link to Paper Search Results by DOI
  81. Enantioselective synthesis of functionalized cyclopentenone and alkylidenecyclopentane delivatives from acyclic bis-allylic diol framework., Synlett , 241, 1-8, 1992
    Link to Paper Search Results by DOI

Publications such as books

  1. 2017/04, Regulation of hematopoiesis and hematological disease by TGF-beta and related signaling. doi:10.1101/cshprespect.a027987, Regulation of the Bioavailability of TGF-beta and TGF-beta-Related Proteins, CSHL Press, 2017, 04, Scholarly Book, Joint work, 英語, Naka K., and Hirao A, ISBN 978-1-621820-36-9
  2. 2016, Chronic myeloid leukemia: Methods and Protocols, Springer., Immunological analysis of leukemia stem cells, Springer, 2016, 01, Scholarly Book, Joint work, Naka K. (corresponding author), and Takihara Y.,, ISBN 978-1-4939-4011-0
  3. 2013, TGF-β signaling in Leukemogenesis. , TGF-β in human disease, Springer, Scholarly Book, Joint work, Naka K (corresponding author), Hirao A

Invited Lecture, Oral Presentation, Poster Presentation

  1. Discovery of a novel activin receptor-like kinases (ALKs) inhibitor targeting TGF-beta signaling pathways, Mai Arai, Mitsuharu Hanada, Hideki Moriyama, Hiroshi Ohmoto, Kazuhito Naka, Masaaki Sawa,, American Association for Cancer Research Annual Meeting 2023, 2023/04/14, Without Invitation, English, Orlando, Florida, USA.
  2. G protein-coupled receptor 48 (Gpr48)/Lgr4 is essential for the maintenance of chronic myelogenous leukemia stem cells, Kazuhito Naka, The 7th International Symposium of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science, 2023/02/20, Without Invitation, English
  3. Lysophospholipid metabolism is essential for maintenance of CML stem cells, Kazuhito Naka, The 95th Annual Meeting of the Japanese Biochemical Society, 2022/11/09, With Invitation, Japanese
    Related URL
  4. The lysophospholipid metabolism enzyme Gdpd3 maintains chronic myelogenous leukemia stem cells, Kazuhito Naka, 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy,, 2021/10/07, Without Invitation, English
    Related URL
  5. The lysophospholipid metabolism enzyme Gdpd3 maintains chronic myelogenous leukemia stem cells, Kazuhito Naka, FASEB Science Research Conference, The Lysophospholipid and Related Mediators Conference: From Bench to Clinic, 2021/07/13, With Invitation, English
    Related URL
  6. Lipid Metabolism Specific to CML Stem Cells, Kazuhito Naka, The 12th Japanese Society of Hematology International Symposium 2021, 2021/05/14, With Invitation, English
    Related URL, Attached File's URL
  7. Lysophospholipid metabolism is essential for the maintenance of chronic myelogenous leukemia stem cells, Kazuhito Naka, Ryosuke Ochiai, Eriko Matsubara, Chie Kondo, Kyung-Min Yang, Akira Ooshima and Seong-Jin Kim, The 5th International Symposium of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science, 2021/02/07, Without Invitation, English, Hiroshima, Japan.
    Related URL
  8. The lysophospholipid metabolism enzyme Gdpd3 maintains chronic myelogenous leukemia stem cells., Kazuhito Naka, 2020/10/01, Without Invitation, English, Hiroshima, Japan.
    Related URL
  9. Effects of a Metabolic Inhibitor Targeting S-Adenosyl Methionine (SAM) to a Mouse Model of Acute Radiation Syndrome, Kazuhito Naka, Tomonobu Watanabe, The 4th International Symposium of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science, 2020/02/12, Without Invitation, English, Hiroshima, Japan.
  10. Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells, Kazuhito Naka, 29th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD 2019), 2019/11/07, With Invitation, English, Seoul, Korea
    Related URL, Attached File's URL
  11. Novel Therapeutic Strategy for Targeting CML stem cells (International session), 2014/09/25, With Invitation, English, Yokohama, Japan
  12. Novel therapeutic strategy for eliminating CML stem cells, Kazuhito Naka, BMS CML Symposium 2017 in Hiroshima, 2017/11/16, With Invitation, Japanese, published
  13. Novel therapeutic strategy targeting nutrition specific to CML stem cells, Kazuhito Naka, 2017/10/10, With Invitation, English
  14. Discovery of Novel Therapeutics Targeting CML Stem Cells by Duolink Technology, Kazuhito Naka, 2017/08/30, With Invitation, English, Tokyo
  15. Novel therapeutic strategy targeting nutrient supply of chronic myelogenous leukemia stem cells, Kazuhito Naka, and Wataru Yasu, Special Session TMPD Pathology Meeting Series, 2017/05/11, With Invitation, English, Houston, TX, USA.
  16. Novel therapeutic strategy targeting nutrient supply of chronic myelogenous leukemia stem cells, Kazuhito Naka, Yoshihiro Takihara, Ichinohe Tatsuo, Eisuke Hida, Yukio Kato, Wataru Yasui, and Seong-Jin Kim, Global Academic Programs (GAP) 2017 Conference, 2017/05/09, Without Invitation, English, Houston, TX, USA
  17. Novel therapeutic strategy targeting TGF-beta-Smad3 signaling in CML stem cells, Kazuhito Naka, The 75th Annual Meeting of the Japanese Cancer Association, 2016/10/06, With Invitation, English
  18. Nutrient supply essential for the maintenance of chronic myelogenous leukemia stem cells, Kazuhito Naka, Yoshihiro Takihara, Yukio Kato, Akira Ooshima, and Seong-Jin Kim, 2016/07/22, Without Invitation, English, Hiroshima, Japan
  19. Dipeptide species regulate nutrient signalling essential for the maintenance of chronic myelogenous leukaemia stem cells (Poster), Kazuhito Naka, Akira Ooshima, Yukio Kato, Yoshihiro Takihara, and Seong-Jin Kim, Keystone Symposia, Stem Cells and Cancer., 2016/03/06, Without Invitation, English, Breckenridge, CO, USA.
  20. A Nutrient Supply Essential for CML stem cells, Kazuhito Naka, The 87th of Stem cell biology and Regenerative Medicine forum, 2016/02/08, With Invitation, English, Tokyo, Japan
  21. TGFb Signaling Inhibitor eradicates CML Stem Cells (Poster), Kazuhito Naka, Kaori Ishihara, Yoshie Jomen, Fourth Joint International Symposium on TGF-beta and Cancer, 2015/01/12, Without Invitation, English, Tsukuba, Japan
  22. The Novel Oral TGFbeta Signaling Inhibitor Targets Chronic Myeloid Leukemia Stem Cells (Poster), Kazuhito Naka, Dong-Hyun Kim, Shaoguang Li, Yhun Yhong Sheen, Akira Oshima, Seong-Jin Kim, and Dae-Kee Kim, Sixteenth Annual John Goldman Conference on Chronic Myeloid Leukemia Biology and Therapy, 2014/09/03, Without Invitation, English, Philadelphia, PA, USA
  23. A Novel Therapeutic Approach for Targeting CML Stem Cells (Invited Speaker), Kazuhito Naka, International Symposium on Tumor Biology in Kanazawa, 2014/01/25, With Invitation, English, Kanazawa, Japan
  24. Role of TGF-beta-FOXO Signaling in CML Stem Cells (Poster), Kazuhito Naka, and Atsushi Hirao, 2013/09/26, Estoril, Portugal
  25. A Role of TGF-β-FOXO Signaling in CML Stem Cells (Invited Speaker), Kazuhito Naka, International Symposium on Carcinogenic Spiral and Tumor Biology in Kanazawa, 2013/01/24, With Invitation, English, Kanazawa, Japan
  26. A Role of TGF-β-FOXO Signaling in CML Stem Cells (Invited Speaker), Kazuhito Naka, The 17th Annual Meeting of Korean Society of Cancer Prevention, 2012/11/09, With Invitation, English, Seoul, Korea
  27. A Role of TGF-β-FOXO Signaling in CML Stem Cells (Invited Speaker), Kazuhito Naka, CHA Research Institute Seminar Series,, 2012/02/20, With Invitation, English, Seoul, Korea
  28. Molecular Mechanism Regulating Foxo In Leukemia Initiating Cells of Chronic Myeloid Leukemia (Poster), Kazuhito Naka, Takayuki Hoshii, Yuko Tadokoro, Takako Ooshio, Yukio Kondo, Shinji Nakao, Noboru Motoyama, and Atsushi Hirao,, The 52nd American Society of Hematology Annual meeting and exposition, 2010/12/04, Orlando, FL, USA
  29. Foxo3a is essential for survival of leukemia-initiating cells in chronic myeloid leukemia (Poster), Kazuhito Naka, Takayuki Hoshii, Teruyuki Muraguchi, Yuko Tadokoro, Takako Ooshio, Noboru Motoyama, Masanobu Oshima, Atsushi Hirao, American Association for Cancer Research 101st Annual meeting, 2010/04/17, Washington DC, USA
  30. Foxo3a is essential for survival of chronic myeloid leukemia-initiating cells (Poster), Kazuhito Naka, Takayuki Hoshii, Teruyuki Muraguchi, Takako Ooshio, Noboru Motoyama, Atsushi Hirao, 7th International Society of Stem Cell Research, 2009/07/08, Barcelona, Spain
  31. Prospective identification of leukemic stem cells by promoter activity of nucleostemin gene (Oral Presentation), Kazuhito Naka, Masako Ohmura, Teruyuki Muraguchi,Takayuki Hoshii Atsushi Hirao, 6th International Society of Stem Cell Research, 2008/06/11, Philadelphia, PA, USA
  32. Identification of tumor-initiating cells by using promoter activity of nucleostemin: Evidence for stemness in both normal and malignant tissues (Poster), Kazuhito Naka, Masako Ohmura, Teruyuki Muraguchi,Takayuki Hoshii Atsushi Hirao,, Keystone Symposium, Tumor Suppressors and Stem Cell Biology, 2008/02/24, Vancouver, British Columbia, Canada.
  33. Establishment of a labeling system for hematopoietic stem cells by nucleostemin-enhancer/promoter GFP transgenic mice (Poster), Kazuhito Naka, Masako Ohmura, Toshio Suda, Atsushi Hirao, The 49th American Society of Hematology Annual meeting and exposition, 2007/12/08, Atlanta, USA
  34. Establishment of a labeling system for hematopoietic stem cells by nucleostemin-enhancer/promoter driving GFP transgenic mice (Poster), Kazuhito Naka, Masako Ohmura, Fumio Arai, Toshio Suda, Atsushi Hirao, , 5th international society of stem cell research,, 2007/06/17, Cairns, Queensland, Australia
  35. A study on establishment of a mouse model for identifying leukemic stem cells (Invited Speaker), Kazuhito Naka, International Symposium on Tumor Biology in Kanazawa 2007, 2007/01/25, With Invitation, English, Kanazawa, Japan
  36. Establishment of a labeling system for hematopoietic stem cells by Nucleostemin-EGFP transgenic mice (Poster), Kazuhito Naka, Masako Ohmura, Fumio Arai, Toshio Suda, Atsushi Hirao, Sixteenth international symposium of the Hiroshima cancer seminar “Cancer Stem Cells, 2006/10/22, Hiroshima, Japan
  37. Interferon resistance of HCV replicons is caused by functional disruption of type I interferon receptors (Poster), Kazuhito Naka, Kazunori Takemoto, Ken-ichi Abe, Hiromichi Dansako, Masanori Ikeda, Kunitada Shimotohno, and Nobuyuki Kato, 12th international symposium on hepatitis C virus and related viruses, 2005/10/02, Montreal, Canada
  38. Hepatitis C Virus NS5B activates TLR3 signaling pathway in non-cancerous hepatocytes (Oral Presentation), Kazuhito Naka, Hiromichi Dansako, Naoya Kobayashi, Masanori Ikeda, and Nobuyuki Kato,, 11th international symposium on hepatitis C virus and related viruses, 2004/10/03, Heidelberg, Germany
  39. Chk2 regulates p53 stabilization by phosphorylating Mdm2 (Poster), Kazuhito Naka, Chen Chen, Hiroshi Yamaguchi, Katsuyuki Tamai, Kyoji Ikeda, Ettore Appella, and Noboru Motoyama, Radiation biology and cancer, 2004/02/18, Dana Point, California, USA.
  40. Establishment of interferon-resistant hepatitis C virus subgenomic replicons (Poster), Kazuhito Naka, Katsuyuki Namba, Takashi Nakamura, Hiromichi Dansako, Akito Nozaki, Kunitada Shimotohno, and Nobuyuki Kato, 0th international meeting on hepatitis C virus and related viruses, 2003/12/02, Kyoto, Japan
  41. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription (Poster), Hiroyuki Takai, Kazuhito Naka, Yuki Okada, Miho Watanabe, Naoki Harada, Shin’ichi Saito, Carl W. Anderson, Ettore Appella, Makoto Nakanishi, Hiroshi Suzuki, Kazuo Nagashima, Hirofumi Sawa, Kyoji Ikeda, Noboru Motoyama, , Cold Spring Harbor Laboratory Symposium, Molecular Genetics of Aging, 2002/10/02, Cold Spring Harbor, New York, USA.
  42. Recruitment of NBS1 into PML Oncogenic Domains via interaction with Sp100 protein (Poster), Kazuhito Naka, Kyoji Ikeda, Noboru Motoyama, Keystone Symposia, 2002/01/22, Keystone, Colorado, USA.
  43. Recruitment of NBS1 into PML Oncogenic Domains via interaction with Sp100 protein (Poster), Kazuhito Naka, Kyoji Ikeda, Noboru Motoyama,, The Salk Institute Meetings and Symposia Oncogenes and Growth Control Meeting, 2001/08/18, La Jolla, California, USA.
  44. Introduction of telomerase to ataxia telangiectasia cells can extend shortened telomeres and bypass replicative senescence (Poster), Kazuhito Naka, Akira Matsuura, Akira Tachibana, Fuyuki Ishikawa, Kyoji Ikeda, Noboru Motoyama,, Cold Spring Harbor Laboratory Symposium, Telomere and Telomerase 2001, 2001/03/28, Cold Spring Harbor, New York, USA.
  45. Introduction of telomerase to ataxia teleangiectasia cells can extend shortened telomeres and bypass replicative senescence (Poster), Kazuhito Naka, Akira Matsuura, Akira Tachibana, Fuyuki Ishikawa, Kyoji Ikeda, Noboru Motoyama, Miami Winter Symposia, cell death and aging, 2001/02/03, Miami Beach, Florida, USA.
  46. Establishment of Immortalized Ataxia Telangiectasia Cells by Telomerase (Poster), Kazuhito Naka, Akira Matsuura, Akira Tachibana, Fuyuki Ishikawa, Kyoji Ikeda, Noboru Motoyama, The International Workshop on Dynamics and Algorithms of Chromosome Function, 2000/11/20, Hiroshima, Japan
  47. Effect of telomere reduction caused by antisense human telomerase RNA (hTR) as a telomerase inhibitor in human gastric cancer cell lines (Poster), Kazuhito Naka, Hiroshi Yokozaki, Wataru Yasui, Hidetoshi Tahara, Eiji Tahara, Eiichi Tahara,, The 10th Annual International Conference of The International Society of Differentiation., 1998/10/03, Houston, Texas, USA.
  48. Effects of 9-cis-retinoic acid on human gastric cancer cell lines (Poster), Kazuhito Naka, Hiroshi Yokozaki, Tamiko Domen, Ken Hayashi, Hiroki Kuniyasu, Wataru Yasui, Reuben Lotan and Eiichi Tahara: , The First International Conference on Gastroenterological Carcinogenesis, , 1996/10/22, Hiroshima, Japan

Patented

  1. Patent, U.S. Patent Application No. 15/560,885, March 26, 2019. June 18, 2019, A composition for inhibiting growth or proliferation of chronic myelogenous leukemia cancer stem cell and a method thereof (Application, WO/2016/159575 A2, October 6th, 2016)
  2. Patent, Therapeutic agent for chronic myeloid leukemia (Application, WO/2016/159301 A1, October 6th, 2016)
  3. Patent, Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same (Application, WO/2016/126028 A1, August 11th, 2016)

Social Activities

History as Peer Reviews of Academic Papers

  1. 2016, Blood Research, Editor, Editorial Board